Tibbets focuses her practice on FDA-regulated product development, marketing and corporate communications as well as the intersection of each of those with corporate strategy and securities disclosure obligations. Her product reach spans biologics, drugs, medical devices, in vitro diagnostics, foods, dietary supplements, and cosmetics. Tibbets advises clients on interactions with FDA, product formulations, clinical trial documentation, adverse event reporting, commercial strategy, product labeling and advertising. She also leads the regulatory due diligence reviews of FDA-regulated M&A targets, potential collaborators and licensees.
“Our FDA practice provides clients with a full spectrum of services from working closely with companies to develop pre-market strategies to advising companies on commercial launches and lifecycle management,” said Mitchell Bloom, Co-Chair of Goodwin’s Life Sciences Practice. “Julie’s notable regulatory experience across multiple industries will be of significant value to our international biotechnology, pharmaceutical and medical technology clients. We are excited to welcome Julie to Goodwin.”
“To keep pace with the dynamic and ever-changing regulatory environment, we continually look for opportunities to evolve our life sciences and FDA regulatory capabilities,” said Kingsley Taft, Co-Chair of Goodwin’s Life Sciences Practice. “Julie’s comprehensive knowledge coupled with her collaborative and entrepreneurial approach to client matters will be a wonderful complement to our core offerings and team. She is a highly-regarded practitioner within the industry and we are delighted she’s joining the firm.”
Tibbets received her J.D. from The University of North Carolina at Chapel Hill and her B.A. from Purdue University. She is admitted to practice in North Carolina and the District of Columbia.
Tibbets is an active member of several professional organizations including the Food and Drug Law Institute, and authors a recurring column in Pharmaceutical Marketing 360. She is also recognized by The Best Lawyers in America for her work in FDA law and has been named a “Rising Star” by Super Lawyers in the food and drug sector.
Tibbets can be reached at JTibbets@goodwinlaw.com and 202.346.4226.
Goodwin’s Life Sciences Practice is deeply experienced in corporate governance, financing and M&A transactions, collaborations and licensing, regulatory matters, and intellectual property law. It was named “Practice Group of the Year” by Law360, which called Goodwin “a top choice for high-profile pharmaceutical clients, particularly in licensing deals, mergers and acquisitions, and initial public offerings.” Goodwin has been recognized by U.S. News and World Report - Best Lawyers as “Biotech Firm of Year” for five out of last six years. In addition, the firm was named 2017 IP Law Firm of the Year by LMG Life Sciences.
With more than 180 lawyers, Goodwin’s Technology Companies practice is one of the largest and most recognized technology practices in the U.S. Consistently rated in the top five most active of all law firms for venture capital, IPOs and M&A, Goodwin draws on its deep experience and network of clients and investors to provide the most effective and efficient counsel for today’s emerging companies. Goodwin supports clients at all stages of the corporate life cycle with legal advisory services ranging from company formation, IP protection, licensing, commercial agreements and venture financing to IPOs, M&A, corporate governance, board matters and more.